
Please try another search
Investing.com - Mirum Pharmaceuticals (NASDAQ: MIRM) reported first quarter EPS of $-0.80, $0.05 better than the analyst estimate of $-0.85. Revenue for the quarter came in at $31.6M versus the...
Mirum Pharmaceuticals (NASDAQ:MIRM), Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029...
Mirum Pharmaceuticals (NASDAQ:MIRM), Inc. (“Mirum”) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of...
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reported Q4 revenue for the quarter at $27.91 million versus the consensus estimate of $24.65 million.
Investing.com - Mirum Pharmaceuticals (NASDAQ: MIRM) reported first quarter EPS of $-0.90, $0.11 better than the analyst estimate of $-1.00. Revenue for the quarter came in at $27.91M versus the...
Investing.com - Mirum Pharmaceuticals (NASDAQ:MIRM) reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Mirum Pharmaceuticals...
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reported Q1 EPS of ($1.17), $0.17 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $12.9 million versus the consensus estimate...
By Mrinalika Roy and Bhanvi Satija (Reuters) -Mirum Pharmaceuticals Inc said on Wednesday its drug became the first U.S. approved therapy for treating itching in patients with a rare liver disorder...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review